口服抗生素不能预防即刻假体乳房再造术后感染或假体丢失
该回顾性研究纳入2008年1月至2020年5月1077例接受即刻假体乳房切除术后乳房再造(PMBR)的女性患者,比较延长抗生素预防(EAP)组与无EAP组的90天结局。多因素分析显示两组手术部位感染、入院、再手术及假体取出率均无显著差异,EAP组革兰阴性感染更常见(P<0.001)。作者结论认为EAP未改善结局,且部分患者出现不良反应。
要点
- EAP组与无EAP组的手术部位感染、入院、再手术及假体取出率均无显著差异。
- EAP组更易发生革兰阴性感染(P<0.001)。
- 13例(2.0%)EAP组女性发生过敏反应,4例(0.6%)发生艰难梭菌结肠炎。
核心结论
- PMBR后EAP未改善结局,虽未加重临床结局,但相关感染微生物学差异可能使其更难治疗,且小部分女性出现EAP不良反应。
研究设计与样本
- 回顾性研究,纳入2008年1月至2020年5月接受即刻假体PMBR的1077例女性患者。
- 所有患者术前及术后24小时内接受静脉抗生素;2016年10月前患者额外口服抗生素至引流管拔除,此后该做法被废止。
- 比较EAP阳性组与EAP阴性组的90天结局,采用描述性统计和多因素logistic回归分析。
主要发现
- EAP阳性组1004侧乳房,EAP阴性组683侧乳房;361例(21.4%)重建为胸肌前。
- 多因素分析显示两组手术部位感染(OR 0.83;95%CI 0.56-1.25;P=0.38)、入院(OR 0.78;95%CI 0.41-1.48;P=0.44)、再手术(OR 1.01;95%CI 0.68-1.48;P=0.97)及假体取出率(OR 1.06;95%CI 0.66-1.71;P=0.81)均无差异。
- EAP阳性组更易发生革兰阴性感染(P<0.001)。
- 13例(2.0%)EAP阳性组女性发生过敏反应,4例(0.6%)发生艰难梭菌结肠炎,归因于EAP。
临床怎么用
- 作者结论认为PMBR后EAP未改善结局;原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Infectious complications following implant-based postmastectomy breast reconstruction (PMBR) are a significant cause of morbidity. Nationwide, antimicrobial stewardship efforts have sought to reduce the use of prophylactic antibiotics postoperatively. However, there are conflicting data regarding the utility of extended antibiotic prophylaxis (EAP) after PMBR, and many surgeons continue to prescribe them. METHODS: The authors conducted a retrospective study of 1077 women who underwent immediate prosthetic PMBR from January of 2008 to May of 2020. All patients received intravenous antibiotics preoperatively and up to 24 hours postoperatively. Before October of 2016, patients were also prescribed oral antibiotics until drain removal; thereafter, this practice was abandoned. Ninety-day outcomes were compared between EAP-positive and EAP-negative patients. Descriptive statistics and multivariable logistic regression analysis were used to assess the efficacy of EAP in preventing infection-related complications. RESULTS: There were 1004 breasts in the EAP-positive group and 683 in the EAP-negative group. Three hundred sixty-one reconstructions (21.4%) were prepectoral. Multivariable analysis demonstrated no difference in surgical-site infection (OR, 0.83; 95% CI, 0.56 to 1.25; P = 0.38), admission (OR, 0.78; 95% CI, 0.41 to 1.48; P = 0.44), reoperation (OR, 1.01; 95% CI, 0.68 to 1.48; P = 0.97), or explantation rates (OR, 1.06; 95% CI, 0.66 to 1.71; P = 0.81) between the EAP groups. The EAP-positive group was more likely to develop Gram-negative infections ( P < 0.001). Thirteen EAP-positive women (2.0%) developed allergic reactions, and four (0.6%) developed Clostridium difficile colitis attributable to the EAP. CONCLUSIONS: EAP after PMBR did not improve outcomes. Although use of EAP did not appear to worsen clinical outcomes, marked differences in the microbiology of associated infections may render them more difficult to treat. Moreover, a small but significant proportion of women experienced adverse reactions to the EAP. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.
引用
- Sisco M, Kuchta K, Alva D, et al. Oral Antibiotics Do Not Prevent Infection or Implant Loss after Immediate Prosthetic Breast Reconstruction. Plast Reconstr Surg. 2022. PMID: 36729481. doi:10.1097/PRS.0000000000010073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。